The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetics of escalated dose of imatinib in patients with advanced gastrointestinal stromal tumors.
Changhoon Yoo
No relevant relationships to disclose
Min-Hee Ryu
No relevant relationships to disclose
Baek-Yeol Ryoo
No relevant relationships to disclose
Inkeun Park
No relevant relationships to disclose
Mo Youl Beck
No relevant relationships to disclose
Yoon-Koo Kang
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis